Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has a beta value of 0.87 and has seen 71.16 million shares traded in the last trading session. The company, currently valued at $4.16B, closed the last trade at $10.64 per share which meant it gained $0.11 on the day or 1.04% during that session. The RXRX stock price is -47.93% off its 52-week high price of $15.74 and 47.37% above the 52-week low of $5.60.
The consensus among analysts is that Recursion Pharmaceuticals Inc (RXRX) is Buy stock at the moment, with a recommendation rating of 2.43. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.42.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Sporting 1.04% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the RXRX stock price touched $10.64 or saw a rise of 13.92%. Year-to-date, Recursion Pharmaceuticals Inc shares have moved 57.40%, while the 5-day performance has seen it change 39.08%. Over the past 30 days, the shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) have changed 66.25%.
Wall Street analysts have a consensus price target for the stock at $11, which means that the shares’ value could jump 3.27% from current levels. The projected low price target is $6.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -12.78% off the targeted high while a plunge would see the stock lose 43.61% from current levels.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
The company’s shares have gained 59.04% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 52.11%.
7 analysts offering their estimates for the company have set an average revenue estimate of 19.04M for the current quarter. 3 have an estimated revenue figure of 12M for the next ending quarter. Year-ago sales stood 10.89M and 13.79M respectively for this quarter and the next, and analysts expect sales will grow by 74.85% for the current quarter and 52.11% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -43.41% over the past 5 years. Earnings growth for 2025 is a modest 2.61% while over the next 5 years, the company’s earnings are expected to increase by 4.49%.
RXRX Dividends
Recursion Pharmaceuticals Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
The top two institutional holders are ARK INVESTMENT MANAGEMENT LLC with over 28.14 million shares worth more than $211.07 million. As of 2024-06-30, ARK INVESTMENT MANAGEMENT LLC held 11.924% of shares outstanding.
The other major institutional holder is BAILLIE GIFFORD & CO, with the holding of over 26.59 million shares as of 2024-06-30. The firm’s total holdings are worth over $199.42 million and represent 11.266% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF . As of Dec 31, 2024 , the former fund manager holds about 4.76% shares in the company for having 18.28 shares of worth $194.48 million while later fund manager owns 11.51 shares of worth $122.44 million as of Dec 31, 2024 , which makes it owner of about 3.00% of company’s outstanding stock.
